Reproductive Sciences

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, April 10, 2024
PFS, University, Epithelium, UPMC Magee-Womens Hospital, Pancreatic cancer, Triple-negative breast cancer, Colorectal cancer, Research, Cisplatin, AIM, MD, Peritoneum, Gynecologic Oncology (journal), UPMC, Gynaecology, Disease, Liver, Patient, CXCL10, CXCL11, Reproductive Sciences, Progression-free survival, Data analysis, Neoplasm, Biomarker, CXCL9, Cancer, RNA, Ovarian cancer, Medical imaging

See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .

Key Points: 
  • See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
  • Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer ( 1 , 2 ) metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver .
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors.
  • Additionally, Keynote-100’s median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study.

What Women Can Do to Take Control of Their Reproductive Health & Rights Post-Roe, according to Mary Jane Minkin, M.D.

Retrieved on: 
Wednesday, April 17, 2024
Women, FDA, Baby, Maternity, Convenience Store, Health, Consumer, Pharmaceutical, General Health, Retail, Education, Medroxyprogesterone acetate, Roe v. Wade, 7-Eleven, LARC, Misoprostol, Condom, Safety, Pregnancy, Woman, Cadence, Policy, Supreme court, OTC, Mini, Planned Parenthood, Mifepristone, Reproductive rights, Abortion, Uterus, Yale University, Arm, Birth, Parenthood, Reproductive Sciences, Long-acting reversible contraceptives, Confidentiality, Progesterone, Pharmacy, Birth control

Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University, stresses the critical need for accessible contraception and reproductive health tools to prevent unintended pregnancies.

Key Points: 
  • Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University, stresses the critical need for accessible contraception and reproductive health tools to prevent unintended pregnancies.
  • "The rollback on reproductive rights makes it absolutely imperative that we prioritize comprehensive access to contraception," says Dr. Minkin.
  • "It's not just about preventing pregnancy; it's about preserving the autonomy and health of women across the nation."
  • "We must ensure that women of all ages have the education, resources, and confidentiality to make informed choices about their reproductive health.

Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, April 2, 2024
Uterus, Gynaecology, Longevity, Reproductive Sciences, Patient, Collaboration, University, EMA, MD, European Medicines Agency, European, PIPE, Esophageal atresia, Yale school, OTCQB, Cryptocurrency

The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.

Key Points: 
  • The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.
  • Company’s subsidiary in Hong Kong launched its longevity product business in Asia, generating more than $100,000 in 2023 sales.
  • Entered into securities purchase agreements with accredited investors for a $6 million private investment in public equity (PIPE) financing.
  • Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported fourth quarter and full year 2023 financial results.

CCRM FERTILITY WELCOMES REGIONAL DIRECTOR OF CLINICAL REPRODUCTIVE GENETICS, DR. JASMINE ALY, TO JERSEY CITY TEAM

Retrieved on: 
Wednesday, March 27, 2024
ART, WRNMMC, Obstetrics, PCOS, Gynaecology, Obesity, Polycystic disease, Reproductive Sciences, Science, NHGRI, Genetic distance, FACOG, Genetics, COVID-19, Patient, Empathy, Medical genetics, Cooper University Hospital, Research, African Americans, USUHS, Fibroid, Reproduction, Assisted reproductive technology, IRMS, NIH, Polycystic ovary syndrome, Outline of health sciences, Reproductive endocrinology and infertility, Publication, Fertility, REI, Birth control

JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey. Dr. Aly holds the rare distinction of being a triple-specialized physician as an Obstetrician-Gynecologist, Reproductive Endocrinologist, and Medical Geneticist.

Key Points: 
  • JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey.
  • As Regional Director of Clinical Reproductive Genetics, Dr. Aly will bring her expertise to the CCRM Fertility team and aims to leverage her comprehensive fellowship training in genetics to further advance the field and better serve patients.
  • As an esteemed reproductive endocrinologist, she will utilize cutting-edge  technology and innovative scientific techniques to ensure patient success rates continue to rise.
  • "Dr. Aly's expertise in genetics is an invaluable attribute that will redefine care at CCRM | IRMS," notes CCRM Fertility CEO, Bob LaGalia.

Setting New Year's Health Resolutions? OB-GYN Offers Guidance on Prioritizing Women’s Sexual and Reproductive Well-Being in 2024

Retrieved on: 
Tuesday, January 16, 2024
Social Media, Health, Blogging, Consumer, Other Health, Other Education, Public Relations, Investor Relations, Parenting, Marketing, Managed Care, Education, General Health, Communications, Women, Woman, Hand, Vulva, Supermarket, Fertility, Vitamin, Hygiene, Gynaecology, Condom, ECS, Female, Vagina, Menstrual cycle, Birth, Q&A, Irritation, Reproductive Sciences, Bacteria, Water, STI, Pain, Probiotic, Pleasure, Communication, Birth control

, OB-GYN, Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine, offers insights into the common questions women might have as they set health goals for 2024.

Key Points: 
  • , OB-GYN, Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine, offers insights into the common questions women might have as they set health goals for 2024.
  • A balanced diet is crucial for overall health, including female sexual health.
  • Regular checkups with your health care provider can help address any concerns related to sexual health.
  • “As we settle into 2024, it’s important to remember that individual health needs vary," adds Dr. Minkin.

World-Renowned Surgeon Joins NYU Langone Health as Division Director of Minimally Invasive and Specialty Gynecologic Surgery

Retrieved on: 
Wednesday, January 3, 2024
Hospital, Division, NYU Langone Health, Research, Minimally invasive procedure, NYU, University, Endometriosis, Patient, Reproductive Sciences, Gynaecology, Nursing

NEW YORK, Jan. 3, 2024 /PRNewswire/ -- A leading gynecologic surgeon, Ted T. Lee, MD , has joined NYU Langone Health as director of the Division of Minimally Invasive and Specialty Gynecologic Surgery and chief of surgical innovation for gynecology in NYU Grossman School of Medicine's Department of Obstetrics and Gynecology , effective January 1.

Key Points: 
  • NEW YORK, Jan. 3, 2024 /PRNewswire/ -- A leading gynecologic surgeon, Ted T. Lee, MD , has joined NYU Langone Health as director of the Division of Minimally Invasive and Specialty Gynecologic Surgery and chief of surgical innovation for gynecology in NYU Grossman School of Medicine's Department of Obstetrics and Gynecology , effective January 1.
  • In his new roles, Dr. Lee will oversee minimally invasive surgical services that treat common and complex gynecologic conditions at NYU Langone's Manhattan campus and NYU Langone Hospital—Brooklyn.
  • "I am dedicated to advancing the boundaries of minimally invasive gynecologic surgery, ensuring world-class, patient-centered care," said Dr. Lee.
  • "This is an exciting chapter and I look forward to contributing to the continued excellence in women's health care at NYU Langone."

Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus

Retrieved on: 
Monday, December 4, 2023
Quality of life, Woman, Regeneration, Infertility, Abortion, Endometrium, SRA, Harvard Apparatus, Health, Yale School of Medicine, Curettage, MD, Doctor of Philosophy, Fertility, Endometriosis, OTCQB, Reproductive Sciences, Gastrointestinal tract, Uterus, Miscarriage, Gynaecology, Yale school, Birth control

The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage.

Key Points: 
  • The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage.
  • Any event that causes damage to the endometrium may lead to the development of IUAs, resulting in menstrual disturbances, infertility and (recurrent) pregnancy loss.
  • IUAs have a debilitating impact on the health and quality of life in women of childbearing age while the economic burden is substantial.
  • This will be a unique opportunity to test our technology in a hollow organ outside the gastrointestinal tract,” commented William Fodor, PhD, Chief Scientific Officer.

Mirvie Announces Completion of Enrollment of 10,000 Person Landmark Research Study for Pregnancy Health

Retrieved on: 
Tuesday, November 14, 2023
Science, Women, Biotechnology, Research, Health, Baby, Maternity, Consumer, Clinical Trials, Disease, Reproductive Sciences, Risk, Mortality, Pregnancy, UC San Diego Health, Ochsner Health System, Pre-eclampsia, Blood, University, RNA, Birth control, Dietary supplement, Gynaecology, Ephraim Mirvis, Obstetrics

Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.

Key Points: 
  • Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.
  • “This monumental effort represents a new chapter for pregnancy health,” said Maneesh Jain, CEO and co-founder of Mirvie.
  • “Today, we face a massive crisis in maternal health, and innovative solutions are desperately needed.
  • The audacious scale of this generalizable study – involving over 10,000 individuals – creates the largest and richest biobank of pregnancy transcriptomes ever to exist.”
    Led by internationally renowned experts in pregnancy health, the U.S.-based study seeks to understand how RNA messages found in expectant mothers’ blood can predict life-threatening pregnancy complications.

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
Monday, November 13, 2023
Theta, Inner circle, Georgetown University, Brown University, Woman, Oncology nursing, Associate, Reproductive Sciences, Research, Radiation, Cervical cancer, Gynecologic Oncology (journal), Overlook Medical Center, Pathology, National Cancer Institute, Roswell Park, Mount Sinai School, Women's studies, Multimedia, Professional, Fellow, Thomas Jefferson University, Vaginal cancer, Medication, Health, Alpert Medical School, Vulvar cancer, ABOG, Uterine cancer, Exceptional Women in Publishing, Ovarian cancer, MD, Japanese Cancer Association, FACOG, Delta Sigma, Women's health, Atlantic Women's Colleges Conference, Carol, Volunteering, Flexner Report, Estate (law), Biology, Education, Birth control, Science, Gynaecology, Medicine, Cancer, New York (magazine), Neuroscience, Obstetrics

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital

Retrieved on: 
Wednesday, November 8, 2023
Survival, Gynaecology, Ovarian cancer, Drug discovery, MD, Pathology, UPMC Magee-Womens Hospital, Senior, Translational medicine, Reproductive Sciences, Ovary, Machine learning, ML, Patient, UPMC, Medical imaging, Obstetrics

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital.

Key Points: 
  • PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital.
  • The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.
  • “This study incorporated one of the largest sets of multi-omic data from 235 ovarian cancer patients, to identify the key features from these datasets driving overall survival endpoints.
  • “Our collaboration with Predictive Oncology brought cutting-edge AI capabilities, using multi-omic features to deliver strong predictive models with high levels of accuracy.